CD274 and non-small cell lung carcinoma: Third, the NSCLC cohort of patients included in our study was heterogeneous, also including patients receiving anti-PD-(L)1 treatment in combination with chemotherapy or other immune checkpoint inhibitors and in different treatment lines, which may have influenced our results.